Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Jiangsu Hengrui Medicine
Pharma
Roche-Innovent, AstraZeneca, Viatris and more—Fierce Pharma Asia
Roche and Ideaya separately licensed ADCs from Chinese firms. Experts weighed in on AZ's China probes. A Viatris plant got a warning letter. And more.
Angus Liu
Jan 3, 2025 8:37am
Astellas, Otsuka, Samsung Biologics—Fierce Pharma Asia
Oct 25, 2024 8:43am
Hengrui, Sanofi and Aslan—Fierce Pharma Asia
Jul 19, 2024 9:48am
Inside the FDA concerns that sank Hengrui's PD-1 drug filing
Jul 16, 2024 4:50pm
Eisai, Takeda, BIOSECURE—Fierce Pharma Asia
Jul 12, 2024 9:05am
UPDATED: Elevar, Hengrui eye accelerated refile for PD-1 combo
Jul 12, 2024 12:08am